Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value

Journal of Neuro-Oncology

Volumn 44, Issue 3, 1999, Pages 255-266

  Heesters, Mart A A M ^a   Koudstaal, Jan ^a   Go, K Gwan ^a   Molenaar, Willemina M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Glioma; Immunohistochemistry; MIB 1; TUNEL

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

APOPTOSIS; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; DNA STRAND BREAKAGE; GLIOBLASTOMA; GLIOMA; GROWTH RATE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; OLIGODENDROGLIOMA; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR GROWTH;

ADOLESCENT; ADULT; ANTIGENS, NUCLEAR; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL DIVISION; DNA DAMAGE; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MIDDLE AGED; NUCLEAR PROTEINS; OLIGODENDROGLIOMA; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0033493770     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006398613605     Document Type: Article

References (38)

1. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, Hirakawa K: Prognostic significance of Ki-67 labelling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77-2: 373-380, 1996
2. Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villani R, Belotti C: Prognostic factors in oligodendroglioma. Can J Neurol Sci 24-4: 313-319, 1997
3. Kros JM, Hop WC, Godschalk JJCJ, Krishnadath KK: Prognostic value of the proliferation related antigen Ki-67 in oligodendrogliomas. Cancer 78-5: 1107-1113, 1996
4. Schiffer D, Cavalla P, Chio A, Richaiardi P, Giordana MT: Proliferative activity and prognosis of low grade astrocytoma. J Neuro-Oncol 34: 31-35, 1997
5. Nakamura M, Konishi N, Tsunoda S, Hiasa Y, Tsuzuki T, Inui T, Sakaki T: Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 80-2: 242-249, 1997
6. Schiffer D, Dutto A, Cavalla P, Chio A, Migheli A, Piva R: Role of apoptosis in the prognosis of oligodendrogliomas. Neurochem Int 31-2: 245-250, 1997
7. Hsu DW, Louis DN, Efird JT, Hedley-White ET: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropath Exp Neurol 56-8: 857-865, 1997
8. Daumas Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas. A simple and reproducible method. Cancer 62: 2152-2165, 1988
9. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79-7: 1381-1393, 1997
10. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumors. Brain pathol 3: 255-268, 1993
11. Going JJ: Efficiently estimated histologic cell counts. Hum Pathol 25: 333-336, 1994
12. Davis RL, Onda K, Shubuya M, Lamborn K, Hoshino T: Proliferation markers in gliomas: a comparison of BUDR, Ki-67 and MIB-1. J Neuro-Oncol 24: 9-12, 1995
13. Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T: Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 74-7: 1921-1926, 1994
14. Kordek R, Hironishi M, Liberski PP, Yanagihara R, Carleton Gajdusek D: Apoptosis in glial tumours as determined by in situ nonradioactive labeling of DNA breaks. Acta Neuropathol 91: 112-116, 1996
15. Shoji Y, Saegusa M, Takano Y, Ohbu M, Okayasu I: Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. J Clin Pathol 49: 134-138, 1996
16. Van Slooten HJ, van de Vijver MJ, van de Velde CJH, van Dierendonck: Loss of bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 77-5: 789-796, 1998
17. Nakagawa S, Shiraishi T, Kihara S, Tabuchi K: Detection of DNA strand breaks associated with apoptosis in human brain tumors. Virchows Arch 427: 175-179, 1995
18. Ellison DW, Steart PV, Gatter KC, Weller RO: Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 21: 352-361, 1995
19. Evans G, Littlewood T: Apoptosis, a matter of life and cell death. Science 281: 1317-1322, 1998
20. Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O'Fallon JR, Earle JD, Laws JR, Okazaki H: Radiation therapy in the management of low grade supratentorial astrocytomas. J Neurosurg 70: 853-861, 1989
21. North CA, North RB, Epstein JA, Piantadosi S, Wharam MD: Low grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer 66: 6-14, 1990
22. Mornex F, Nayel H, Taillandier L: Radiation therapy for malignant astrocytomas in adults. Radiotherapy and Oncology 27: 181-191, 1993
23. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic astrocytomas in adults. J Neurosurg 71: 487-493, 1993
24. Sheline GE: Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys 18: 793-803, 1990
25. Ho DM, WongT, Hsu C, Ting L, Chiang H: MIB-1 labelling index in nonpilocytic astrocytoma of childhood. Cancer 82-12: 2459-2466, 1998
26. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helin HJ: Prognostication of astrocytoma patient survival by Ki-67 (Mib-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275-282, 1994
27. Krouwer HG, Davis RL, Silver P, Prados M: Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74: 399-406, 1991
28. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H: Role of gemistocytes in astrocytoma progression. Lab Invest 76-2: 277-284, 1997
29. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T: Ki-67 immunoreactivity in human central nervous system tumours: a study with MIB-1 monoclonal antibody on archival material. Acta Neuropathol 87: 47-54, 1994
30. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, Macdonald D, Cairncross G: Supratentorial low grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15-4: 1294-1301, 1997
31. Schiffer D, Cavalla P, Migheli A, Chio A, Giordana MT, Marino S, Attanasio A: Apoptosis and cell proliferation in human neuroepithelial tumors. Neuroscience Letters 195: 81-84, 1995
32. Coons SW, Johnson PC, Pearl DK: The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 41-4: 878-884, 1997
33. Dehghani F, Schachenmayr AL, Laun A, Korf HW: Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathologica 95: 493-504, 1998
34. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chod kiewicz JP: Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neuro-Oncol 34: 61-78, 1997
35. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB: Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 86: 121-130, 1997
36. Kirkegaard LJ, De Rose PB, Yao B, Cohen C: Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas. Prognostic significance. Am J Clin Pathol 109-1: 69-74, 1998
37. Heegaard S, Sommer HM, Broholm H, Braendstrup O: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76-10: 1809-1813, 1995
38. Wharton SB, Hamilton FA, Chant WK, Chan KK, Anderson JR: Proliferation and cell death in oligoden-drogliomas. Neuropath Appl Neurobiol 24: 21-28, 1998